Quest Diagnostics (NYSE:DGX) SVP Sells $1,629,400.00 in Stock

Quest Diagnostics Incorporated (NYSE:DGX) SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the sale, the senior vice president directly owned 13,510 shares of the company’s stock, valued at $2,702,000. This represents a 37.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Quest Diagnostics Price Performance

DGX opened at $204.06 on Thursday. The company has a fifty day moving average price of $194.74 and a two-hundred day moving average price of $191.70. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.08 and a current ratio of 1.18. Quest Diagnostics Incorporated has a 52 week low of $164.65 and a 52 week high of $213.50. The firm has a market capitalization of $22.59 billion, a PE ratio of 22.55, a P/E/G ratio of 2.44 and a beta of 0.59.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Tuesday, April 21st. The medical research company reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The firm had revenue of $2.90 billion during the quarter, compared to analyst estimates of $2.83 billion. During the same quarter in the previous year, the business earned $1.94 EPS. The business’s quarterly revenue was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. As a group, analysts anticipate that Quest Diagnostics Incorporated will post 10.72 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Stockholders of record on Wednesday, July 8th will be issued a $0.86 dividend. The ex-dividend date of this dividend is Wednesday, July 8th. This represents a $3.44 annualized dividend and a dividend yield of 1.7%. Quest Diagnostics’s payout ratio is 38.01%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DGX. Evercore set a $225.00 price target on shares of Quest Diagnostics in a report on Tuesday, April 21st. Robert W. Baird boosted their price target on shares of Quest Diagnostics from $224.00 to $229.00 and gave the company a “neutral” rating in a report on Wednesday, April 22nd. Barclays boosted their price target on shares of Quest Diagnostics from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Wednesday, April 22nd. Truist Financial boosted their price target on shares of Quest Diagnostics from $220.00 to $225.00 and gave the company a “hold” rating in a report on Wednesday, April 22nd. Finally, Mizuho boosted their price target on shares of Quest Diagnostics from $210.00 to $235.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, Quest Diagnostics has an average rating of “Moderate Buy” and an average price target of $216.58.

Institutional Investors Weigh In On Quest Diagnostics

Institutional investors have recently added to or reduced their stakes in the stock. Key Financial Inc lifted its position in Quest Diagnostics by 1,728.6% in the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 121 shares in the last quarter. Quattro Advisors LLC bought a new stake in Quest Diagnostics in the 4th quarter valued at $25,000. JFS Wealth Advisors LLC lifted its position in Quest Diagnostics by 114.3% in the 4th quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 80 shares in the last quarter. Sittner & Nelson LLC bought a new stake in Quest Diagnostics in the 4th quarter valued at $29,000. Finally, DV Equities LLC bought a new stake in Quest Diagnostics in the 4th quarter valued at $27,000. 88.06% of the stock is owned by institutional investors.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.